Certolizumab pegol: A polyethylene glycolated fab′ fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease

Reviews in Gastroenterological Disorders

Volumn 8, Issue 4, 2008, Pages 240-253

  Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Adalimumab; Certolizumab pegol; Crohn's disease; Etanercept; Infliximab; Plaque psoriasis; Rheumatoid arthritis; TNF biologic response modifiers; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANOREXIGENIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; BALSALAZIDE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OLSALAZINE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALOPECIA; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANXIETY; APLASTIC ANEMIA; ARTHRALGIA; BIPOLAR DISORDER; CLINICAL TRIAL; CROHN DISEASE; DEMYELINATING DISEASE; DEPRESSION; DERMATITIS; DISEASE SEVERITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA NODOSUM; FEVER; FRUSTRATION; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE OBSTRUCTION; KIDNEY FAILURE; LEUKOPENIA; LYMPHADENOPATHY; NAUSEA; NEPHRITIS; NEURALGIA; OPTIC NEURITIS; PANCYTOPENIA; PATIENT MONITORING; PERICARDIAL EFFUSION; PERICARDITIS; PROTEIN BLOOD LEVEL; PSORIASIS; RETINA HEMORRHAGE; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SEIZURE; SERUM SICKNESS; SIDE EFFECT; SUICIDE ATTEMPT; THROMBOCYTOPENIA;_ABDOMINAL PAIN; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UVEITIS; VASCULITIS; WEAKNESS;

CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS;

EID: 58149096144     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther. 2004;6(suppl 2):S12-S18.
2. Ardizzone S, Porro GB. Biologic therapy for inflammatory bowel disease. Drugs. 2005;65:2253-2286.
3. Amgen. Package literature for Enbrel. January 2007. Available at: www.enbrel.com. Accessed March 28, 2007.
4. Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin N Am. 2004;33:251-269.
5. Abbott Laboratories. Humira [package insert]. North Chicago, IL: Abbott Laboratories; February 2008.
6. Centocor. Remicade [package insert]. Malvern, PA: Centocor; April 2007.
7. Lim WC, Hanauer SB. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord. 2004;4:66-85.
8. Gramlick A, Henry A, Fossati G, Nesbitt A. Neutralization of soluble and membrane TNFα by infliximab, adalimumab, and certolizumab pegol using a p55 TNF receptor-specific bioassay [abstract]. Presented at Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
9. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin N Am. 2006;35:757-773.
10. Schwartzman S, Fleischmann R, Morgan GJ. Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? Arthritis Res Ther. 2004;6(suppl 2):S3-S11.
11. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled phase III study (PRECiSE 1) [abstract 745]. Gastroenterology. 2006;130:A-107.
12. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
13. UCB Pharma. UCB submits biologies license application to FDA for new treatment in Crohn's disease [press release, March 2, 2006]. Available at: http://www.ucb-pharma.com/media_centre/2585.asp Accessed September 26, 2006.
14. UCB. Cimzia [package insert]. Smyrna, GA: UCB; April 2008.
15. Choy EHS, Hazleman B, Smith M, et al. Efficacy of novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology. 2002;41:1133-1137.
16. UCB. CIMZIA shows promise in treatment of psoriasis [press release, July 18, 2006]. Available at: http://www.ucb-pharma.com/media_centre/press_releases/ medical/2006.asp. Accessed July 18, 2006.
17. Nesbitt AM, Gramlick A, Fossati G. Neutralization of soluble and membrane tumor necrosis factor-α (TNF-α) by infliximab, adalimumab, or certolizumab pegol using p55 or p75 TNF-α receptor-specific bioassays [abstract W1634]. Presented at Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
18. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13:1323-1332.
19. Baker M, Stephens S. Investigation of the pharmacokinetics properties of certolizumab pegol, an anti-TNF agent [abstract 750808]. Presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 20-25, 2006; Las Vegas, NV.
20. Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Certolizumab pegol, a humanised anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase III study (Precise) Gut. 2005;54(suppl VII):A82.
21. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther. 2004;20:1337-1346.
22. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238.
23. Schreiber S, Feagan B, Hanauer SB, et al. Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn's disease (CD): results from two phase III studies (PRECiSE program) [abstract T1126]. Presented at Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
24. Schreiber S, Lawrence IC, McColm JA, et al. How effective is anti-TNF-α therapy? A re-analysis of the PRECiSE 2 maintenance trial of monthly subcutaneous certolizumab pegol in active Crohn's disease using remission to redefine all efficacy measures [abstract T1140]. Presented at Digestive Disease Week; May 20-25, 2006; Los Angeles, CA.
25. UCB. UCB submits Biologics license application to FDA for new treatment in Crohn's disease [press release, March 2, 2006]. Brussels, Belgium and Atlanta, GA: UCB; March 2, 2006.
26. Schreiber S, Khaliq-Kareemi M, Lawrence IC, et aI. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.
27. UCB Pharma. UCB submits biologics license application to FDA for new treatment in Crohn's disease [press release, March 2, 2006]. Available at: http:// www.ucb-pharma.com/media_centre/2585.asp Accessed September 26, 2006.
28. Feagan BG, Keininger DL, Coteur G, Schreiber S. Impact of Crohn's disease and treatment with Certolizumab pegol 400 mg every 4 weeks on patient-reported health status: Data from PRECiSE 2 [abstract 751277]. Presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 20-25, 2006; Las Vegas, NV.
29. Brown M, Thomsen OO, Purcaru O, Schreiber S. PRECisE2 data demonstrate a high association between work productivity, daily activities and clinical endpoints in Crohn's disease [abstract 750810]. Presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 20-25, 2006; Las Vegas, NV.
30. Feagan B, Coteur G, Keininger D. Certolizumab pegol relieves the symptoms of Crohn's disease, including those rated as the most severe [abstract]. Inflamm Bowel Dis. 2008;14(suppl):S13.
31. Schreiber S, Panes J, Mason D, et al. Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from Precise 2 and its extension studies (Precise 3 and 4) [abstract T1133]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
32. Schreiber S, Panes J, Mason D, et al. Efficacy and tolerability of certolizumab pegol are sustained over 18 months: data from PRECISE 2 and its extension studies (PRECISE 3 and 4) [abstract]. Inflamm Bowel Dis. 2008;14(suppl):S8.
33. Lichtenstein GR, Mitchev K, D'Haens G. Re-induction with certolizumab pegol following disease exacerbation during maintenance therapy is effective to regain response and remission [abstract T1120]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
34. Danese S, Mocciaro F, Guidi L, et al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use [letter]. Inflamm Bowel Dis. In press.
35. Feagan B, Tan S, Brown M. Impact of certolizumab pegol on quality-adjusted life-years in two induction and maintenance trials in patients with active Crohn's disease [abstract 943]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
36. D'Haens G, Mitchev K, Sandborn WJ. Response and remission at 18 months of certolizumab pegol in patients with active Crohn's disease is not influenced by rapidity and magnitude of induction: an analysis of Precise 2 and 3 [abstract T1126]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
37. Hommes DW. Response to certolizumab pegol induction is not steroid-dependent in patients with active Crohn's disease [abstract T1149]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
38. Vermeire S, Collin B, Mitchev K, et al. Certolizumab pegol in patients with Crohn's disease who failed treatment with other anti-TNFs: data from a compassionate use program [abstract]. Inflamm Bowel Dis. 2008;14(suppl):S29.
39. Vermeire S, Abreu MT, D'Haens G, et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the Welcome Study [abstract 494]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
40. Hanauer SB, Schreiber S, Thomsen OO, et al. Predictors of response in patients with active Crohn's disease treated with certolizumab pegol: a multiple regression analysis of Precise 2 data [abstract T1129]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
41. Fleischmann R, Mason D, Cohen S. Efficacy and safety of certolizumab pegol monotherapy in patients with rheumatoid arthritis failing previous DMARD therapy [abstract]. Ann Rheum Dis. 2007;66(suppl 2):169.
42. Fleischmann R, Keininger DL, Tahiri-Fitzgerald E, Mease P. Certolizumab pegol monotherapy 400 mg every 4 weeks improves physical functioning and reduces pain in patients with rheumatoid arthritis who have previously failed DMARD therapy [abstract]. Ann Rheum Dis. 2007;66(suppl 2):170.
43. Strand V, Keininger D, Tahiri-Fitzgerald E, Fleischmann R. Certolizumab pegol monotherapy 400 mg every 4 weeks improves health-related quality of life and relieves fatigue in patients with rheumatoid arthritis who have previously failed DMARD therapy [abstract]. Ann Rheum Dis. 2007;66(suppl 2):188.
44. Strand V, Brown M, Purcaru O, Richard L. Certolizumab pegol monotherapy improves productivity in patients with active rheumatoid arthritis: results from a phase III randomized controlled trial [abstract]. Ann Rheum Dis. 2007;66(suppl 2):274.
45. Keystone E, Mason D, Combe B. The anti-TNF certolizumab pegol in combination with methotrexate is significantly more effective than methotrexate alone in the treatment of patients with active rheumatoid arthritis: preliminary results from the RAPID 1 study [abstract]. Ann Rheum Dis 2007;66(suppl 2):55.
46. Smolen J, Brzezicki J, Mason D, Kavanaugh A. Efficacy and safety of certolizumab pegol in combination with methotrexate (MTX) in patients with active rheumatoid arthritis despite MTX therapy: results from the RAPID 2 study [abstract]. Ann Rheum Dis. 2007;66(suppl 2):187.
47. Schiff M, Keininger DL, Tahiri-Fitzgerald E. Certolizumab pegol added onto methotrexate improves physical functioning and reduces pain in patients with rheumatoid arthritis who have an incomplete response to methotrexate: data from RAPID 2 [abstract]. Ann Rheum Dis. 2007;66(suppl 2):187.
48. A study of the safety and effectiveness of lyophilized certolizumab pegol in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00175877?term= certolizumab&rank=2. Accessed June 6, 2008.
49. A study of the safety of liquid certolizumab pegol in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis. Available at: http://www. clinicaltrials.gov/ct2/show/NCT00160641?term=certolizumab&rank=4. Accessed June 6, 2008.
50. Study to assess the safety of CDP870 for up to 30 months following reintroduction of treatment. Available at: http://www.clinicaltrials.gov/ct2/ show/NCT00160706?term=certolizumab&rank=7. Accessed June 6, 2008.
51. Open label long-term safety study of CDP870 (certolizumab pegol) for patients with rheumatoid arthritis. Available at: http://www.clinicaltrials.gov/ ct2/show/NCT00160693?term=certolizumab&rank=8. Accessed June 6, 2008.
52. Dosing flexibility study in patients with RA. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00580840?term=certolizumab&rank= 14. Accessed June 6, 2008.
53. A study of liquid certolizumab pegol as additional medication to methotrexate in the treatnent of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00160602?term= certolizumab&rank=22. Accessed June 6, 2008.
54. Rheumatoid arthritis (RA) moderate to low disease activity study. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00674362?term= certolizumab&rank=30. Accessed June 6, 2008.
55. Reich K, Tasset C, Ortonne J. Efficacy and safety of certolizumab pegol, in patients with chronic plaque psoriasis: preliminary results of a randomized, double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis. 2007;66(suppl 2):251.
56. Ortonne JP, Reich K, Sterry W, Terpstra I. Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: results from a double-blind, placebo-controlled trial [abstract]. J Am Acad Dermatol. 2008;58(suppl 2):AB4.
57. Ortonne JP, Reich K, Keininger D. Certolizumab pegol improved health-related quality of life in patients with psoriasis: data from a phase II study [abstract]. J Am Acad Dermatol. 2008;58(suppl 2):AB121.
58. Nesbitt AM, Stephens S, Bloomfield R. Neutralising antibodies to certolizumab pegol do not appear to impact on efficacy or safety in patients with Crohn's disease [abstract]. Gut. 2008;57(suppl 1):A142.
59. Nesbitt AM, Brown DT, Stephens S, Foulkes R. Placental transfer and accumulation in milk of the anti-TNF antibody TN3 in rats: immunoglobulin G1 versus PEGylated Fab' [abstract 750882]. Presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 20-25, 2006; Las Vegas, NV.
60. Feagan B, Colombel JF, Present DH, et al. Coadministration of certolizumab pegol with immunosuppressants and/or corticosteroids is not associated with an increased risk of adverse events with Crohn's disease: analysis of pooled data [abstract T1141]. Presented at Digestive Disease Week; May 17-22, 2008; San Diego, CA.
61. U.S. Food and Drug Administration. FDA approves Cimzia to treat Crohn's disease [press release, April 22, 2008]. Available at: http://www.fda.gov/bbs/ topics/NEWS/2008/NEW01821.html. Accessed April 23, 2008.